中医药克服表皮生长因子受体酪氨酸激酶抑制剂耐药的机制研究展望  

Research prospect on the mechanisms of overcoming EGFR-TKIs drug-fast with traditional Chinese medicine

作　　者：郦安琪[1] 舒琦瑾[2] 

机构地区：[1]浙江中医药大学第一临床医学院,杭州310053 [2]浙江中医药大学附属第一医院肿瘤科,杭州310006

出　　处：《中华中医药杂志》2014年第6期1922-1925,共4页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家自然科学基金面上项目(No.81173247)~~

摘　　要：随着厄洛替尼、吉非替尼、埃克替尼等表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)的应用,EGFR突变的非小细胞肺癌患者的PFS和OS得到了延长。然而在临床治疗过程中,EGFR-TKIs耐药的出现往往导致治疗最终失败。EGFR-TKIs的耐药包括原发性耐药和获得性耐药,尽管目前对EGFR-TKIs耐药机制的研究取得了一些成果,但是许多耐药机制并未明确。中医药联合EGFR-TKIs治疗进展期非小细胞肺癌中在临床中可见到明确疗效,而研究中医药在对抗EGFR-TKIs耐药有很大的前景。文章主要论述了原发性、获得性耐药机制和中医药在对抗EGFR-TKIs耐药机制上的进展。As the application of the epidermal growth factor receptor-tyrosine kinase inhibitors, such as hrlotinib hydrochloride, gefinitib and icotinib hydrochloride, the progression free survival and overall survival of NSCLC patients who harbor EGFR gene mutation got to be extended. In the process of clinical treatment the EGFR-TKIs resistance may lead to the failure of treatment. EGFR-TKIs resistance included primary drug resistance and acquired drug resistance. Although the EGFR- TKIs resistance had made some achievements, the mechanism was not clear. Treating advanced non-small cell lung cancer with integrated traditional Chinese medicine and TKIs had a clear effect in clinic. It has broad prospects to study overcoming the EGFR-TKIs drug-fast with traditional Chinese medicine. In this review, it discussed about the mechanisms of primary drug resistance and acquired drug resistance and research progress about overcoming the EGFR-TKIs drug-fast with traditional Chinese medicine.

关 键 词：表皮生长因子受体酪氨酸激酶抑制剂 原发性耐药 获得性耐药 中医药 

分 类 号：R734.2[医药卫生—肿瘤]